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Letter to the Editor

Evaluation of two commercial assays for the rapid confirmation of OXA-48 like
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Over the past decade, carbapenemase-producing
Enterobacteriaceae (CPE) have emerged worldwide
as significant pathogens (1). Rapid and accurate
confirmation of carbapenemase production is essential
to guide antimicrobial therapy and to ensure prompt
implementation of infection control measures to prevent
spread of CPE (2).
The aim of this study was to assess the performance of
2 commercially available assays for the rapid detection of
CPE with OXA-48 like carbapenemases. These included a
commercially-available PCR, i.e. the BDMAX CRE assay
(Becton Dickinson, Canada), and a commercially available
immunochromatographic assay, i.e. Resist-3 O.K.N K-SeT
(Coris BioConcept, Belgium).
In a previous CPE surveillance program at the Hacettepe
University Adult and Oncology Hospitals, Turkey, 279
isolates of Klebsiella pneumoniae were recovered from
rectal screening swabs from unique patients. Two hundred
and seventy consecutive isolates produced OXA-48 like
carbapenemases and one produced IMP carbapenemase,
as confirmed by in-house PCR methods (3). Species
identification was confirmed by MALDI-TOF MS
(Bruker, Coventry, UK). One hundred and ninety-nine
of these isolates were selected for inclusion in this study
including 192 isolates with OXA-48 like carbapenemases
and 7 isolates without any carbapenemase. The MIC of
carbapenems for these isolates ranged widely from <1 to
>32 mg/L (3).
Prior to testing for carbapenemase activity, each isolate
was retrieved from storage at –80 °C and subcultured
on Mueller–Hinton agar (Oxoid) with incubation for
18 h at 37 °C in air. Each isolate was tested with the
2 commercial assays in exact accordance with the
manufacturer’s instructions. The BD MAX CRE assay is a
research use only automated PCR assay allowing detection
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and distinction of the 3 most commonly encountered
carbapenemase genes: KPC, OXA-48, and NDM. The
assay automates sample extraction, amplification, and
detection by using real-time PCR with a total running time
of 90–120 min (depending on batch size). There is sample
processing control in the extraction tube that undergoes
the extraction, concentration, and amplification steps to
monitor the assay inhibition as well as process inefficiency
due to instrument or reagent failure.
The
RESIST-3
O.K.N.
K-SeT
is
an
immunochromatographic cartridge assay that employs a
membrane technology with colloidal gold nanoparticles.
This test also allows detection and distinction of KPC,
NDM, and OXA-48 like carbapenemases from a single
colony of Enterobacteriaceae. The result is visible within
15 min in the form of red lines on the strip. For both
assays, the preanalytical handling time was 5–7 min.
In blind testing, both the BD MAX CRE and the
RESIST-3 O.K.N. K-SeT successfully detected OXA-48 like
carbapenemases in 192 isolates and gave negative results
for the 7 negative controls. No other carbapenemases
were detected and no repeat tests were necessary. Thus the
sensitivity and specificity of the 2 assays were 100%.
No instrumentation is required for the RESIST-3
O.K.N. K-SeT and a result can be generated in around 20
min, compared with at least 95 min for the BD MAX CRE
assay (including handling time). The cost of the BD MAX
assay is approximately 28.7 Euros per sample compared
with 10.5 Euros for the RESIST-3 O.K.N. K-SeT.
A range of laboratory assays has been developed
for detection of carbapenemases that can be applied to
bacterial colonies. These include matrix-assisted laserdesorption/ionisation time-of-flight mass spectrometry
(MALDI-TOF MS), immunochromatographic assays,
susceptibility tests that employ β-lactamase inhibitors
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and chromogenic tests such as the CARBA-NP test (4–
6). Alternatively, the presence of carbapenemases may
be inferred by detection of target genes using molecular
assays, e.g., using PCR or microarrays (7). OXA-48
carbapenemase was first reported in Klebsiella pneumoniae
isolated in İstanbul in 2001 (8). Since then, OXA-48 has
become the predominant carbapenemase type in Turkey
and many European countries. In some phenotypic assays,
detection of some OXA-48 producers has proven to be
problematic due to a low level of carbapenemase activity
(resulting in low levels of resistance to carbapenems)
and the lack of a specific inhibitor to assist detection (9).
Recent epidemiological studies have shown that OXA-48
is the most prevalent carbapenemase in many European
countries such as France, Spain, and Belgium and also
in the Middle East, North Africa, and Turkey (10). In
the present study, we showed that both commercial
assays are highly effective for detection of OXA-48 like
carbapenemase producers and that either assay could
constitute a suitable first line test for investigation of
suspected CPE. A limitation of both tests is their inability
to detect VIM carbapenemase and, to a lesser extent,
IMP carbapenemase, and a negative test might therefore
necessitate a second test to rule out the presence of these

metalloenzymes. In a setting such as Turkey, where OXA48 is by far the dominant carbapenemase enzyme, this is
an acceptable limitation. High levels of performance were
also reported by Glupczynski et al. (11), who challenged
the assay with a well-defined collection of 112 carbapenemresistant Enterobactericeae including a range of species
with OXA-48-like, NDM, and KPC enzymes.
When comparing the 2 commercial assays there are
several advantages of the RESIST-3 O.K.N. K-SeT. No
instrumentation is required for the RESIST-3 O.K.N.
K-SeT and a result can be generated in around 20 min,
compared with at least 95 min for the BD MAX CRE
assay. The cost of the BD MAX assay is approximately
28.7 Euros per sample compared with 10.5 Euros for the
RESIST-3 O.K.N. K-SeT. Compared with phenotypic
assays that detect general carbapenemase activity (e.g., the
modified Hodge test, the CARBA NP test, or MALDI-TOF
MS), both assays have the inherent limitation that some
carbapenemases will not be detected, but they have the
advantage that they allow for differentiation of the 3 major
types of carbapenemases. We conclude that both assays
are convenient, accurate, and rapid ‘first line’ tests for
confirmation of OXA-48 like carbapenemase producers.
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